Table 1.
Characteristics by long-term outcome category
| Characteristic | Total | Consumption/symptom group | |||
|---|---|---|---|---|---|
| >=1 serving and no more than oral/pharyngeal symptoms, n=9 | Symptoms or less than one serving, n=23 | P value | |||
| Baseline characteristics | Baseline Age, median (range) years | 9 (6-16) | 8 (6-16) | 10 (6-16) | 0.73 |
| Sex, n (%) male | 21 (66%) | 6 (67%) | 15 (65%) | 0.64 | |
| Presence of Eczema, n(%) | 18 (56%) | 6 (67%) | 12 (52%) | 0.37 | |
| Study assignment, n (%) study 1 | 16 (50%) | 5 (56%) | 11 (48%) | 0.50 | |
| Baseline CM IgE, median (range), kUa/L | 31 (1-314) | 25 (1-73) | 41 (5-314) | 0.04 | |
| Baseline SPT wheal size, median (range) mm | 9 (5-21.5) | 8.5 (5-11.5) | 9.5 (6-21.5) | 0.14 | |
| Baseline threshold, median (range) mg milk protein | 40 (40-1350) | 40 (40-1350) | 40 (40-140) | 0.79 | |
| Symptoms with initial treatment | Median percentage of doses with symptom (range) | ||||
| Gastrointestinal | 1.9% (0-44%) | 0.6% (0-44%) | 2.3% (0-16%) | 0.03 | |
| Lower respiratory | 0.6% (0-7.7%) | 0% (0-1.8%) | 1.0% (0-7.7%) | 0.04 | |
| Skin | 0.4% (0-47%) | 0% (0-0.7%) | 0.4% (0-47%) | 0.06 | |
| Median percentage of doses requiring treatment (range) | |||||
| Anti-histamines | 3.3% (0-59%) | 2.2% (0-20%) | 4.5% (0-59%) | 0.13 | |
| Beta-agonist | 0.3% (0-8.3%) | 0% (0-0.9%) | 0.6% (0-8.3%) | 0.03 | |
| Early outcomes | CM IgE at 3 months maintenance*, median (range) kUa/L | 26 (1-398) | 13 (1-67) | 27 (2-398) | 0.16 |
| SPT wheal size at 3 month maintenance, median (range) mm* | 7 (0-15.5) | 5 (0-15.5) | 7.5 (2-14) | 0.19 | |
| Threshold at 3 months maintenance | 6140 (0-8140) | 8140 (4140-8140) | 4140 (0-8140) | 0.006 | |
| No symptoms at full challenge at 3 months, n(%) | 8 (25%) | 4 (44%) | 4 (17%) | 0.68 | |
| Amount of milk protein that subject went home on**, median (range) grams | 2 (0-8) | 4 (1-8) | 1.5 (0-8) | 0.04 | |
| Later outcomes | Passed tolerance challenge? (study 2), n (%)† | 5 (31%) | 3 (75%) | 2 (17%) | 0.12 |
| Milk IgE in follow-up, median (range) kUa/L†† | 4 (0.4-55) | 4 (0.4-20) | 5 (0.7-55) | 0.19 | |
| SPT wheal size in follow-up median (range) mm†† | 4 (0-15.5) | 0 (0-4.5) | 6 (0-15.5) | 0.02 | |
| Milk IgG4 in follow-up, median (range) ug/ml†† | 19 (8-68) | 18 (8-38) | 19 (10-68) | 0.25 | |
*
n=30
**
Home milk protein recommendations based on food challenge threshold and symptoms
†
n=16
††
n=26
Statistically significant differences are bolded.